Lecanemab: Negative Benefit Assessment for Alzheimer's Medication

Sueddeutsche Zeitung

Lean Left

Factuality

Ownership

In April, the first drug was approved for Alzheimer's disease, which could possibly affect its roots. An institute does not consider it more effective compared to the therapies available so far.

Deutsches Ärzteblatt

Factuality

Ownership

Cologne – The Institute for Quality and Efficiency in Health Care (IQWiG) has found no added benefit for therapy with the Alzheimer's antibody lecanemab. Experts, meanwhile, are criticizing the IQWiG's evaluation method. This applies to both mild cognitive impairment (MCI) compared to a watchful waiting approach...